Sign Out
Pelgraz therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.
Posology: One 6 mg dose (a single pre-filled syringe or pre-filled injecton) of Pelgraz is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
Special populations: Paediatric population: The safety and efficacy of Pelgraz in children and adolescents has not yet been established. Currently available data are described in sections Adverse Reactions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions but no recommendation on a posology can be made.
Patients with renal impairment: No dose change is recommended in patients with renal impairment, including those with end-stage renal disease.
Method of administration: Pelgraz is for subcutaneous use. The injections should be given subcutaneously into the thigh, abdomen or upper arm.
For instructions on handling of the medicinal product before administration, see Cautions for Usage.
Continue with Google